believe study of bimagrumab + semaglutide "Can We Improve the Quality Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The of Semaglutide" June 23, 2025. ADA 85th Scientific Session 🔔The results of the BELIEVE

Long-term efficacy, safety, and real-world muscle function remain key unanswered questions

Comments: Oral tablets: Ozempic 1.5 mg/day and Rybelsus 3 mg/day are not effective dosages for glycemic control

Serious Risks Less common but important: Pancreatitis Kidney problems Gallbladder issues Low blood sugar (especially in diabetics) Thyroid tumor warning (boxed FDA warning) Because tirzepatide is newer, long-term effects are still being studied

Wegovy is specifically for people with a body mass index (BMI) of 30 or more, or 27 or more with weight-related health conditions, including prediabetes and high blood pressure

All of these actions have the effect of reducing appetite, and food intake